These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

344 related articles for article (PubMed ID: 34797518)

  • 1. Comparing Sacubitril/Valsartan Against Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure: A Systematic Review and Network Meta-analysis.
    Teo YN; Teo YH; Syn NL; Yoong CSY; Cheong AJY; Wee CF; Lim YC; Lee CH; Yeo TC; Chai P; Wong RCC; Lin W; Sia CH
    Clin Drug Investig; 2022 Jan; 42(1):1-16. PubMed ID: 34797518
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relative Efficacy of Sacubitril-Valsartan, Vericiguat, and SGLT2 Inhibitors in Heart Failure with Reduced Ejection Fraction: a Systematic Review and Network Meta-Analysis.
    Aimo A; Pateras K; Stamatelopoulos K; Bayes-Genis A; Lombardi CM; Passino C; Emdin M; Georgiopoulos G
    Cardiovasc Drugs Ther; 2021 Oct; 35(5):1067-1076. PubMed ID: 33074526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of sacubitril/valsartan in patients with heart failure and chronic kidney disease: A meta-analysis.
    Kang H; Zhang J; Zhang X; Qin G; Wang K; Deng Z; Fang Y; Chen G
    Eur J Pharmacol; 2020 Oct; 884():173444. PubMed ID: 32739172
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of sacubitril-valsartan in patients with heart failure: a systematic review and meta-analysis of randomized clinical trials: A PRISMA-compliant article.
    Lin J; Zhou J; Xie G; Liu J
    Medicine (Baltimore); 2021 Dec; 100(52):e28231. PubMed ID: 34967357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative efficacy of vericiguat to sacubitril/valsartan for patients with heart failure reduced ejection fraction: Systematic review and network meta-analysis.
    Kang DW; Kang SH; Lee K; Nam K; Kim ES; Yoon JC; Park SK
    Int J Cardiol; 2024 Apr; 400():131786. PubMed ID: 38242507
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure.
    Solomon SD; Vaduganathan M; L Claggett B; Packer M; Zile M; Swedberg K; Rouleau J; A Pfeffer M; Desai A; Lund LH; Kober L; Anand I; Sweitzer N; Linssen G; Merkely B; Luis Arango J; Vinereanu D; Chen CH; Senni M; Sibulo A; Boytsov S; Shi V; Rizkala A; Lefkowitz M; McMurray JJV
    Circulation; 2020 Feb; 141(5):352-361. PubMed ID: 31736342
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) Trial.
    Solomon SD; Claggett B; Desai AS; Packer M; Zile M; Swedberg K; Rouleau JL; Shi VC; Starling RC; Kozan Ö; Dukat A; Lefkowitz MP; McMurray JJ
    Circ Heart Fail; 2016 Mar; 9(3):e002744. PubMed ID: 26915374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systolic blood pressure, cardiovascular outcomes and efficacy and safety of sacubitril/valsartan (LCZ696) in patients with chronic heart failure and reduced ejection fraction: results from PARADIGM-HF.
    Böhm M; Young R; Jhund PS; Solomon SD; Gong J; Lefkowitz MP; Rizkala AR; Rouleau JL; Shi VC; Swedberg K; Zile MR; Packer M; McMurray JJV
    Eur Heart J; 2017 Apr; 38(15):1132-1143. PubMed ID: 28158398
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of sacubitril-valsartan and SGLT2 inhibitors in heart failure with reduced ejection fraction: A systematic review and meta-analysis.
    Mo X; Lu P; Yang X
    Clin Cardiol; 2023 Oct; 46(10):1137-1145. PubMed ID: 37465885
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative Effectiveness of Sacubitril-Valsartan Versus ACE/ARB Therapy in Heart Failure With Reduced Ejection Fraction.
    Tan NY; Sangaralingham LR; Sangaralingham SJ; Yao X; Shah ND; Dunlay SM
    JACC Heart Fail; 2020 Jan; 8(1):43-54. PubMed ID: 31838035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sacubitril/valsartan, sodium-glucose cotransporter 2 inhibitors and vericiguat for congestive heart failure therapy.
    Norre T; Grimm D; Simonsen U
    Basic Clin Pharmacol Toxicol; 2022 Apr; 130(4):425-438. PubMed ID: 35128801
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Dapagliflozin in Patients With HFrEF Treated With Sacubitril/Valsartan: The DAPA-HF Trial.
    Solomon SD; Jhund PS; Claggett BL; Dewan P; Køber L; Kosiborod MN; Martinez FA; Ponikowski P; Sabatine MS; Inzucchi SE; Desai AS; Bengtsson O; Lindholm D; Sjostrand M; Langkilde AM; McMurray JJV
    JACC Heart Fail; 2020 Oct; 8(10):811-818. PubMed ID: 32653447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of neprilysin inhibition on the efficacy and safety of empagliflozin in patients with chronic heart failure and a reduced ejection fraction: the EMPEROR-Reduced trial.
    Packer M; Anker SD; Butler J; Filippatos G; Ferreira JP; Pocock SJ; Rocca HB; Janssens S; Tsutsui H; Zhang J; Brueckmann M; Jamal W; Cotton D; Iwata T; Schnee J; Zannad F;
    Eur Heart J; 2021 Feb; 42(6):671-680. PubMed ID: 33459776
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of sacubitril/valsartan compared with enalapril in patients with chronic heart failure and reduced ejection fraction: Results from PARADIGM-HF India sub-study.
    Jain AR; Aggarwal RK; Rao NS; Billa G; Kumar S
    Indian Heart J; 2020; 72(6):535-540. PubMed ID: 33357641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of sacubitril/valsartan in abnormal renal function patients combined with heart failure: a meta-analysis and systematic analysis.
    Yang X; Jin J; Cheng M; Xu J; Bai Y
    Ren Fail; 2024 Dec; 46(1):2349135. PubMed ID: 38869007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Effect of Sacubitril-Valsartan in Heart Failure Patients With Mid-Range and Preserved Ejection Fraction: A Meta-Analysis.
    Nie D; Xiong B; Qian J; Rong S; Yao Y; Huang J
    Heart Lung Circ; 2021 May; 30(5):683-691. PubMed ID: 33199181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and Safety of Sacubitril/Valsartan Therapy for Acute Decompensated Heart Failure with Reduced Ejection Fraction during the Vulnerable Phase: A Multicenter, Assessor-Blinded, Prospective, Observational, Cohort Study.
    He Y; Lu X; Zheng Y; Song M; Shen B; Nienaber CA; Chen G; Wu F; Zheng J; Zhang W; Wang Y; Li X; Wen H; Yu X; Zhou Y
    Cardiology; 2021; 146(3):335-344. PubMed ID: 33780933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Initiation of Angiotensin-Neprilysin Inhibition After Acute Decompensated Heart Failure: Secondary Analysis of the Open-label Extension of the PIONEER-HF Trial.
    DeVore AD; Braunwald E; Morrow DA; Duffy CI; Ambrosy AP; Chakraborty H; McCague K; Rocha R; Velazquez EJ;
    JAMA Cardiol; 2020 Feb; 5(2):202-207. PubMed ID: 31825471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness Analysis of Sacubitril/Valsartan vs Enalapril in Patients With Heart Failure and Reduced Ejection Fraction.
    Gaziano TA; Fonarow GC; Claggett B; Chan WW; Deschaseaux-Voinet C; Turner SJ; Rouleau JL; Zile MR; McMurray JJ; Solomon SD
    JAMA Cardiol; 2016 Sep; 1(6):666-72. PubMed ID: 27438344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparing the clinical outcomes across different sodium/glucose cotransporter 2 (SGLT2) inhibitors in heart failure patients: a systematic review and network meta-analysis of randomized controlled trials.
    Teo YH; Yoong CSY; Syn NL; Teo YN; Cheong JYA; Lim YC; Lee CH; Yeo TC; Chai P; Wong RCC; Lin W; Sia CH
    Eur J Clin Pharmacol; 2021 Oct; 77(10):1453-1464. PubMed ID: 33942132
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.